Full Press Release Details
HOUSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it will participate in the TD Cowen 45th Annual Health Care Conference. Tvardi management will host investor one-on-one investor meetings on March 3 – 5, 2025.
TD Cowen’s 45th Annual Health Care Conference is taking place March 3 – 5, 2025, at the Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats, and innovative panel discussions hosted by members of the TD Cowen research team that focus on various aspects of the health care industry.
About Tvardi Therapeutics
Tvardi Investor Relations